From the publishers of JADPRO
HR+ HER2- Breast Cancer
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Early-Stage Disease Research Highlights from 2024 San Antonio Breast Cancer Symposium
Last Updated: Tuesday, March 11, 2025
Advertisement
News & Literature Highlights
Anticancer Research
Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer
The Breast
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer
Cancers (Basel)
CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status
Clinical Cancer Research
Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index
Journal of Clinical Oncology
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
Journal of Clinical Oncology
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Journal of Clinical Oncology
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)
Biomedicines
Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer
Journal of Clinical Oncology
Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial
Journal of Clinical Oncology
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
Advertisement
Case Studies
Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer
Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer
First-Line Treatment for Metastatic ER+ HER2- Breast Cancer
Advertisement
Quizzes
Test your knowledge of isolated brain metastasis in BRCA2-mutated HR+ HER2- breast cancer
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer
Test your knowledge on HR-positive, HER2-negative breast cancer